Abstracts tagged "Janus kinase (JAK) and tofacitinib"

Abstract Number: 145 • 2017 Pediatric Rheumatology Symposium
JAK Inhibition Rescues Novel PSMB8 Mutations
J. Brian Shirley¹, Tiphanie Vogel² and Marietta de Guzman³, ¹Allergy, Immunology and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Department of Pediatrics, Division of Immunology, Allergy and Rheumatology and the Center for Human Immunology at Texas Children's Hospital., Baylor College of Medicine, Houston, TX, ³Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: The proteasome associated autoinflammatory syndromes (PRAAS) are characterized by autosomal recessive mutations in the PSMB8 gene. These mutations result in an early childhood overproduction…
Abstract Number: 1595 • 2016 ACR/ARHP Annual Meeting
Magnitude and Duration of Early Response with Tofacitinib: Post-Hoc Analysis of Two Phase 3, Placebo-Controlled Studies
Daniel Aletaha¹, Alan Kivitz², Guillermo Valenzuela³, John Tesser⁴, Steven Hays⁵, Huihua Li⁵, Carol A Connell⁶, Eustratios Bananis⁵, Arif Soonasra⁵ and Josef Smolen⁷, ¹Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria, ²Altoona Center for Clinical Research, Duncansville, PA, ³Integral Rheumatology & Immunology Specialists, Fort Lauderdale, FL, ⁴Arizona Arthritis & Rheumatology Associates, Glendale, AZ, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Groton, CT, ⁷Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. ORAL Solo1 and ORAL Sync2 are two Phase 3 index studies that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].